Pilot study of the antifibrotic effects of the multikinase inhibitor pacritinib in a mouse model of liver fibrosis

BACKGROUND: Fibrotic diseases result from an exuberant response to chronic inflammation. Myelofibrosis is the end result of inflammation in bone, caused by an inflammatory process triggered by production of abnormal myeloid cells driven by mutations affecting the JAK–STAT pathway. Inflammatory cytok...

Descripción completa

Detalles Bibliográficos
Autores principales: Al-Fayoumi, Suliman, Hashiguchi, Taishi, Shirakata, Yuka, Mascarenhas, John, Singer, Jack W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5953271/
https://www.ncbi.nlm.nih.gov/pubmed/29785143
http://dx.doi.org/10.2147/JEP.S150729

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5953271/
https://www.ncbi.nlm.nih.gov/pubmed/29785143
http://dx.doi.org/10.2147/JEP.S150729

Ejemplares similares